

Consolidated Summary – Dr. Reddy's Laboratories Limited

Integrated Annual Report FY 2024–25

Company Overview

Dr. Reddy's Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Guided by its purpose 'Good Health Can't Wait', the company focuses on accelerating access to affordable and innovative medicines across key markets including the U.S., India, Europe, Russia & CIS, China, Brazil, and emerging markets. Its portfolio spans APIs, generics, branded generics, biosimilars, OTC, consumer healthcare, and innovative therapies.

FY 2024–25 Business Performance

FY2025 was a strong year with double-digit revenue growth across all major markets. Total revenue reached ₹325.5 billion with EBITDA of ₹92.1 billion and an EBITDA margin of 28.3%. ROCE stood at approximately 27.7%. Growth was driven by new product launches, strong India performance, steady U.S. growth, and expanding emerging market presence.

Strategic Direction

The company follows a dual strategy of strengthening its core businesses—APIs, generics, biosimilars, and OTC—while building new value pools through consumer healthcare, biosimilars, and novel therapies including NCEs, NBEs, and CAR-T. Strategic acquisitions, partnerships, and licensing agreements support long-term growth.

Innovation and R&D;

Dr. Reddy's invested 8.4% of revenues into R&D during FY2025. The pipeline includes complex generics, biosimilars, peptides, injectables, and oncology assets. Key achievements include approvals and filings across the U.S., Europe, and emerging markets, and progress in biologics and CAR-T capabilities.

Global Operations

The company operates in 83 countries with 23 manufacturing facilities and 9 R&D centers globally. Over 165 product launches were completed during the year, supported by a strong regulatory and compliance track record.

Sustainability and ESG

Sustainability is embedded into business strategy. In FY2025, 68% of power consumption came from renewable sources, 60% carbon neutrality was achieved in direct operations, and the company remained water positive. Significant progress was made in ESG ratings, governance practices, and community impact initiatives.

People and Governance

Dr. Reddy's employed nearly 27,000 people globally, representing 57 nationalities. The company emphasizes ethical governance, board independence, diversity, and leadership development. Continuous upskilling, digital transformation, and employee engagement remain core priorities.

Outlook

Looking ahead, the company remains focused on sustaining growth, managing upcoming patent expiries, scaling innovation-led businesses, and enhancing operational efficiency. Strategic portfolio management, digital enablement, and disciplined capital allocation are expected to support long-term value creation.